Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - Should You Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $17.96, but opened at $18.71. Dianthus Therapeutics shares last traded at $18.93, with a volume of 94,771 shares traded.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. William Blair assumed coverage on Dianthus Therapeutics in a research report on Wednesday. They issued an "outperform" rating on the stock. Guggenheim reissued a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Robert W. Baird cut their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Stock Up 4.0%

The business has a fifty day moving average price of $18.85 and a 200-day moving average price of $20.46. The company has a market cap of $614.74 million, a P/E ratio of -6.64 and a beta of 1.38.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. As a group, research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the company. US Bancorp DE raised its position in shares of Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after acquiring an additional 1,510 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics in the fourth quarter worth approximately $33,000. BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics in the fourth quarter worth approximately $59,000. GAMMA Investing LLC lifted its stake in Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares during the period. Finally, AlphaQuest LLC boosted its holdings in shares of Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after buying an additional 3,072 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.